

## SECTION 1: Identification of the substance/mixture and of the company/undertaking

### 1.1. Product identifier

Trade name or designation of the mixture	MYLERAN TABLETS
Registration number	-
Synonyms	MYLERAN TABLETS 2 MG * BUSULPHAN TABLETS * GW274383X TABLETS * BUSULPHAN, FORMULATED PRODUCT
Issue date	19-December-2014
Version number	16
Revision date	19-December-2014

### 1.2. Relevant identified uses of the substance or mixture and uses advised against

**Identified uses** Medicinal Product.

This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant to medicinal use of the product. In this instance patients should consult prescribing information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate safety data sheet for each ingredient.

**Uses advised against** No other uses are advised.

### 1.3. Details of the supplier of the safety data sheet

GlaxoSmithKline UK  
980 Great West Road  
Brentford, Middlesex TW8 9GS UK  
UK General Information (normal business hours): +44-20-8047-5000  
Email Address: [msds@gsk.com](mailto:msds@gsk.com)  
Website: [www.gsk.com](http://www.gsk.com)

### 1.4. Emergency telephone number

TRANSPORT EMERGENCIES::  
UK In-country toll call: + (44)-870-8200418  
International toll call: +1 703 527 3887  
available 24 hrs/7 days; multi-language response

## SECTION 2: Hazards identification

### 2.1. Classification of the substance or mixture

#### Classification according to Directive 67/548/EEC or 1999/45/EC as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

#### Classification according to Regulation (EC) No 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

### 2.2. Label elements

#### Label according to Regulation (EC) No. 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

**2.3. Other hazards** Caution - Pharmaceutical agent. See section 11 for additional information on health hazards.

## SECTION 3: Composition/information on ingredients

### 3.2. Mixtures

## General information

Chemical name	%	CAS-No. / EC No.	REACH Registration No.	INDEX No.	Notes
Starch	3 - < 5	9005-25-8 232-679-6	-	-	
<b>Classification:</b>	<b>DSD:</b> -				
	<b>CLP:</b> -				
BUSULPHAN	< 2,0	55-98-1 200-250-2	-	-	
<b>Classification:</b>	<b>DSD:</b> Carc. Cat. 1;R45, Muta. Cat. 2;R46, Repr. Cat. 1;R60-61, T+;R28, Xn;R48/20/22, Xi;R36/37/38				
	<b>CLP:</b> Acute Tox. 2;H300, Skin Irrit. 2;H315, Eye Irrit. 2;H319, STOT SE 3;H335, Muta. 1B;H340, Carc. 1A;H350, Repr. 1A;H360FD, STOT RE 2;H373				
MAGNESIUM STEARATE	< 1	557-04-0 209-150-3	-	-	
<b>Classification:</b>	<b>DSD:</b> -				
	<b>CLP:</b> -				
Titanium dioxide	< 1	13463-67-7 236-675-5	-	-	
<b>Classification:</b>	<b>DSD:</b> -				
	<b>CLP:</b> -				

Other components below reportable levels >90

### List of abbreviations and symbols that may be used above

CLP: Regulation No. 1272/2008.

DSD: Directive 67/548/EEC.

M: M-factor

vPvB: very persistent and very bioaccumulative substance.

PBT: persistent, bioaccumulative and toxic substance.

#: This substance has been assigned Community workplace exposure limit(s).

**Composition comments** The full text for all R- and H-phrases is displayed in section 16.

## SECTION 4: First aid measures

**General information** In the case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). Ensure that medical personnel are aware of the material(s) involved, and take precautions to protect themselves.

### 4.1. Description of first aid measures

<b>Inhalation</b>	Move to fresh air. If breathing is difficult, trained personnel should give oxygen. Call a physician if symptoms develop or persist. Under normal conditions of intended use, this material is not expected to be an inhalation hazard.
<b>Skin contact</b>	Immediately flush skin with plenty of water. Take off contaminated clothing and wash before reuse. Get medical attention if symptoms occur.
<b>Eye contact</b>	Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
<b>Ingestion</b>	If swallowed, rinse mouth with water (only if the person is conscious). If ingestion of a large amount does occur, call a poison control centre immediately. Do not induce vomiting without advice from poison control center.

**4.2. Most important symptoms and effects, both acute and delayed** Dusts may irritate the respiratory tract, skin and eyes. The following adverse effects have been noted with therapeutic use of this material: bone marrow toxicity; seizures; nausea; vomiting; symptoms of hypersensitivity (such as skin rash, hives, itching). Additional effects of overexposure may occur.

**4.3. Indication of any immediate medical attention and special treatment needed** No specific antidotes are recommended. Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information centre.

## SECTION 5: Firefighting measures

**General fire hazards** No unusual fire or explosion hazards noted.

### 5.1. Extinguishing media

**Suitable extinguishing media** Water. Foam. Dry chemical powder. Carbon dioxide (CO<sub>2</sub>).

<b>Unsuitable extinguishing media</b>	None known.
<b>5.2. Special hazards arising from the substance or mixture</b>	During fire, gases hazardous to health may be formed.
<b>5.3. Advice for firefighters</b>	
<b>Special protective equipment for firefighters</b>	Self-contained breathing apparatus and full protective clothing must be worn in case of fire.
<b>Special fire fighting procedures</b>	Move containers from fire area if you can do so without risk.
<b>Specific methods</b>	Use standard firefighting procedures and consider the hazards of other involved materials.

## SECTION 6: Accidental release measures

### 6.1. Personal precautions, protective equipment and emergency procedures

**For non-emergency personnel** Keep unnecessary personnel away. Keep upwind. Keep out of low areas. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. For personal protection, see section 8.

**For emergency responders** Keep unnecessary personnel away. Use personal protection recommended in Section 8 of the SDS.

**6.2. Environmental precautions** Avoid discharge into drains, water courses or onto the ground.

**6.3. Methods and material for containment and cleaning up** Stop the flow of material, if this is without risk. Prevent entry into waterways, sewer, basements or confined areas. Following product recovery, flush area with water.

**6.4. Reference to other sections** For personal protection, see section 8. For waste disposal, see section 13 of the SDS.

## SECTION 7: Handling and storage

**7.1. Precautions for safe handling** Avoid breaking or crushing tablets. Avoid prolonged exposure. Observe good industrial hygiene practices.

**7.2. Conditions for safe storage, including any incompatibilities** Store in original tightly closed container. Store away from incompatible materials (see Section 10 of the SDS).

**7.3. Specific end use(s)** Medicinal Product.

## SECTION 8: Exposure controls/personal protection

### 8.1. Control parameters

#### Occupational exposure limits

##### GSK

Components	Type	Value	Note
BUSULPHAN (CAS 55-98-1)	8 HR TWA	1 mcg/m <sup>3</sup>	REPRODUCTIVE HAZARD, CARCINOGEN REPRODUCTIVE HAZARD, CARCINOGEN
	OHC	5	

**Biological limit values** No biological exposure limits noted for the ingredient(s).

**Recommended monitoring procedures** Follow standard monitoring procedures.

**Derived no-effect level (DNEL)** Not available.

**Predicted no effect concentrations (PNECs)** Not available.

#### Exposure guidelines

### 8.2. Exposure controls

**Appropriate engineering controls** Consider segregating operations, use of enclosures and sealed transfer systems.

### Individual protection measures, such as personal protective equipment

**General information** Personal protection equipment should be chosen according to the CEN standards and in discussion with the supplier of the personal protective equipment. Follow all local regulations if personal protective equipment (PPE) is used in the workplace.

**Eye/face protection** Not normally needed. If contact is likely, safety glasses with side shields are recommended. (e.g. EN 166).

**Skin protection**

<b>- Hand protection</b>	The choice of an appropriate glove does not only depend on its material but also on other quality features and is different from one producer to the other. Glove selection must take into account any solvents and other hazards present. Select suitable chemical resistant protective gloves (EN 374) with a protective index 6 (>480min permeation time).
<b>- Other</b>	Wear suitable protective clothing as protection against splashing or contamination. (EN 14605 for splashes, EN ISO 13982 for dust).
<b>Respiratory protection</b>	When workers are facing concentrations above the exposure limit they must use appropriate certified respirators.
<b>Thermal hazards</b>	Wear appropriate thermal protective clothing, when necessary.
<b>Hygiene measures</b>	Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to remove contaminants. For advice on suitable monitoring methods, seek guidance from a qualified environment, health and safety professional. New or expectant mothers might be at greater risk from overexposure. Risk assessments must take this into consideration. Female employees anticipating pregnancy or with a confirmed pregnancy must be encouraged to notify an occupational health professional or their line manager. This will act as the trigger for individual re-assessment of the employee's work practices.

#### Environmental exposure controls

<b>Hazard guidance and control recommendations</b>	Environmental manager must be informed of all major releases.
--	---

## SECTION 9: Physical and chemical properties

### 9.1. Information on basic physical and chemical properties

#### Appearance

<b>Physical state</b>	Solid.
<b>Form</b>	Tablet.
<b>Colour</b>	White
<b>Odour</b>	Not available.
<b>Odour threshold</b>	Not available.
<b>pH</b>	Not available.
<b>Melting point/freezing point</b>	Not available.
<b>Initial boiling point and boiling range</b>	Not available.
<b>Flash point</b>	Not available.
<b>Evaporation rate</b>	Not available.
<b>Flammability (solid, gas)</b>	Not available.

#### Upper/lower flammability or explosive limits

<b>Flammability limit - lower (%)</b>	Not available.
<b>Flammability limit - upper (%)</b>	Not available.

<b>Vapour pressure</b>	Not available.
<b>Vapour density</b>	Not available.
<b>Relative density</b>	Not available.

#### Solubility(ies)

<b>Solubility (water)</b>	Not available.
<b>Solubility (other)</b>	Not available.

<b>Partition coefficient (n-octanol/water)</b>	Not available.
--	----------------

<b>Auto-ignition temperature</b>	Not available.
----------------------------------	----------------

<b>Decomposition temperature</b>	Not available.
----------------------------------	----------------

<b>Viscosity</b>	Not available.
------------------	----------------

<b>Explosive properties</b>	Not available.
-----------------------------	----------------

<b>Oxidizing properties</b>	Not available.
-----------------------------	----------------

<b>9.2. Other information</b>	No relevant additional information available.
-------------------------------	---

## SECTION 10: Stability and reactivity

<b>10.1. Reactivity</b>	The product is stable and non-reactive under normal conditions of use, storage and transport.
-------------------------	---

<b>10.2. Chemical stability</b>	Material is stable under normal conditions.
---------------------------------	---

<b>10.3. Possibility of hazardous reactions</b>	No dangerous reaction known under conditions of normal use.
<b>10.4. Conditions to avoid</b>	Contact with incompatible materials.
<b>10.5. Incompatible materials</b>	Strong oxidising agents.
<b>10.6. Hazardous decomposition products</b>	None known. Irritating and/or toxic fumes and gases may be emitted upon the product's decomposition.

## SECTION 11: Toxicological information

**General information** Occupational exposure to the substance or mixture may cause adverse effects.

### Information on likely routes of exposure

<b>Inhalation</b>	Health injuries are not known or expected under normal use. Under normal conditions of intended use, this material is not expected to be an inhalation hazard.
<b>Skin contact</b>	Health injuries are not known or expected under normal use. May cause an allergic skin reaction.
<b>Eye contact</b>	Health injuries are not known or expected under normal use. Dust or powder may irritate eye tissue.
<b>Ingestion</b>	Health injuries are not known or expected under normal use. May be harmful if swallowed. However, ingestion is not likely to be a primary route of occupational exposure.

**Symptoms** Dusts may irritate the respiratory tract, skin and eyes. The following adverse effects have been noted with therapeutic use of this material: bone marrow toxicity; seizures; nausea; vomiting; symptoms of hypersensitivity (such as skin rash, hives, itching). Additional effects of overexposure may occur.

### 11.1. Information on toxicological effects

**Acute toxicity** Health injuries are not known or expected under normal use. May be harmful if swallowed.

Components	Species	Test results
BUSULPHAN (CAS 55-98-1)		
<b>Acute</b>		
<i>Oral</i>		
LD50	Rat	14 mg/kg
MAGNESIUM STEARATE (CAS 557-04-0)		
<b>Acute</b>		
<i>Oral</i>		
LD50	Rat	> 2000 mg/kg
Titanium dioxide (CAS 13463-67-7)		
<b>Acute</b>		
<i>Inhalation</i>		
LC50	Rat	6820 mcg/m <sup>3</sup>
<i>Oral</i>		
LD50	Rat	> 24 g/kg
<b>Chronic</b>		
<i>Inhalation</i>		
LOEC	Rat	8,6 mg/m <sup>3</sup> , 1 years TiO <sub>2</sub> accumulated in interstitial macrophages, aggregated interstitial cells and particle laden macrophages in lymphoid tissue.
NOAEC	Rat	250 mg/m <sup>3</sup> , 2 years Highest dose 5 mg/m <sup>3</sup> , 24 months
<b>Subacute</b>		
<i>Inhalation</i>		
LOEL	Rat	0,1 - 35 mg/m <sup>3</sup> , 4 weeks Mild macrophage hyperplasia, no change in bronchio-alveolar lavage fluid.
NOAEC	Guinea pig	26 mg/m <sup>3</sup> , 3 weeks No evidence of significant inflammation in respiratory tract.
<i>Oral</i>		
NOAEL	Rat	100000 ppm, 14 Day Dietary study, highest dose tested.

Components	Species	Test results
<b>Subchronic</b> <i>Inhalation</i> LOEC	Rat	3,2 - 20 mg/m <sup>3</sup> , 8 min Accumulation of TiO <sub>2</sub> in macrophages and evidence of pulmonary inflammation.
* Estimates for product may be based on additional component data not shown.		
<b>Skin corrosion/irritation</b>	Health injuries are not known or expected under normal use.	
<b>Irritation Corrosion - Skin</b> TITANIUM DIOXIDE		0, Literature data Result: Non-irritant Species: Guinea pig 0, Literature data Result: Non-irritant Species: Human Acute dermal irritation; OECD 404, Literature data Result: Non-irritant Species: Rabbit
<b>Irritation Corrosion - Skin: P.I.I. value</b> MAGNESIUM STEARATE		0
<b>Serious eye damage/eye irritation</b>	Health injuries are not known or expected under normal use. Dust or powder may irritate eye tissue.	
<b>Eye</b> TITANIUM DIOXIDE		OECD 405, Literature data Result: Mild irritant Species: Rabbit
<b>Eye / Kay and Calandra class - Intact</b> MAGNESIUM STEARATE		4 Recovery Period: 2 days
<b>Respiratory sensitisation</b>	Not available.	
<b>Skin sensitisation</b>	Health injuries are not known or expected under normal use. Allergic skin reactions might occur following repeated contact with this material in susceptible individuals.	
<b>Sensitisation</b> TITANIUM DIOXIDE		5 % Optimisation Test, Literature data - Vehicle: petrolatum Result: negative Species: Guinea pig Test Duration: 48 hour exposure Patch test, Literature data Result: negative Species: Human
<b>Germ cell mutagenicity</b>	Health injuries are not known or expected under normal use. The ingredient busulphan has caused genetic toxicity in laboratory studies.	
<b>Mutagenicity</b> TITANIUM DIOXIDE		Ames, Literature data Result: negative Micronucleus Assay in vitro, CHO cells, Literature data Result: negative Micronucleus Assay in vitro, cultured human peripheral lymphocytes, Literature data Result: positive Syrian Hamster Embryo (SHE) cell transformation assay Result: negative WIL2-NS HPRT/ t-Thioguanidine - Human B-Cell lymphoblastoid, Literature data Result: positive
<b>Carcinogenicity</b> TITANIUM DIOXIDE	Health injuries are not known or expected under normal use. Contains a material (busulphan, titanium dioxide) classified as a carcinogen by external agencies. 0,5 mg/m <sup>3</sup> , Literature data Result: negative Species: Rat Test Duration: 24 months 0,72 - 14,8 mg/m <sup>3</sup> , Literature data Result: negative Species: Mouse	

**Carcinogenicity**  
TITANIUM DIOXIDE

10 - 250 mg/m<sup>3</sup>, Dietary study - Literature data.  
Result: Inflammation at all doses with alveolar/bronchiolar adenoma at the highest concentration.  
Species: Rat  
Test Duration: 24 months  
25000 - 50000 ppm, Dietary study  
Result: negative  
Species: Mouse  
25000 - 50000 ppm, Dietary study - Literature data.  
Result: negative  
Species: Rat  
7,2 - 14,8 mg/m<sup>3</sup>, Literature data  
Result: Lung tumour  
Species: Rat  
Test Duration: 24 months

**IARC Monographs. Overall Evaluation of Carcinogenicity**

BUSULPHAN (CAS 55-98-1) 1 Carcinogenic to humans.  
Titanium dioxide (CAS 13463-67-7) 2B Possibly carcinogenic to humans.

**Reproductive toxicity** Health injuries are not known or expected under normal use. The ingredient busulphan has caused adverse effects on the development of unborn offspring in animal studies.

**Specific target organ toxicity - single exposure** None known.

**Specific target organ toxicity - repeated exposure** None known.

**Aspiration hazard** Not available.

**Mixture versus substance information** No information available.

**Other information** Caution - Pharmaceutical agent. Occupational exposure to the substance or mixture may cause adverse effects.

**SECTION 12: Ecological information**

**12.1. Toxicity** Not expected to be harmful to aquatic organisms.

Components	Species	Test results
MAGNESIUM STEARATE (CAS 557-04-0)		
<b>Aquatic</b>		
<i>Acute</i>		
Fish	EC50 Orange-red killfish (Adult Oryzias latipes)	130 mg/l, 96 hours
Titanium dioxide (CAS 13463-67-7)		
<b>Aquatic</b>		
<i>Acute</i>		
Crustacea	EC50 Water flea (Daphnia magna)	> 1000 mg/l, 48 hours Static test

\* Estimates for product may be based on additional component data not shown.

**12.2. Persistence and degradability**

**Photolysis**

**Half-life (Photolysis-atmospheric)**

MAGNESIUM STEARATE 17 Hours Estimated

**UV/visible spectrum wavelength**

MAGNESIUM STEARATE 210 nm

**Hydrolysis**

**Half-life (Hydrolysis-neutral)**

BUSULPHAN < 24 Hours Measured

**Biodegradability**

**Percent degradation (Aerobic biodegradation-inherent)**

MAGNESIUM STEARATE 77 %, 28 days BOD

**Percent degradation (Aerobic biodegradation-ready)**

MAGNESIUM STEARATE 95 %, 22 days Sturm test

**Percent degradation (Aerobic biodegradation-soil)**

MAGNESIUM STEARATE 50 %, 13 days

**12.3. Bioaccumulative potential**

<b>Partition coefficient n-octanol/water (log Kow)</b>	
BUSULPHAN	-0,52
<b>Bioconcentration factor (BCF)</b>	
MAGNESIUM STEARATE	> 9999 Estimated

#### 12.4. Mobility in soil

##### Adsorption

##### Soil/sediment sorption - log Koc

MAGNESIUM STEARATE 5,86 Estimated

#### Mobility in general

**12.5. Results of PBT  
and vPvB  
assessment** Not available.

**12.6. Other adverse effects** Not available.

### SECTION 13: Disposal considerations

#### 13.1. Waste treatment methods

<b>Residual waste</b>	Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see: Disposal instructions). Avoid discharge into water courses or onto the ground.
<b>Contaminated packaging</b>	Empty containers should be taken to an approved waste handling site for recycling or disposal. Since emptied containers may retain product residue, follow label warnings even after container is emptied.
<b>EU waste code</b>	The Waste code should be assigned in discussion between the user, the producer and the waste disposal company.
<b>Disposal methods/information</b>	Collect and reclaim or dispose in sealed containers at licensed waste disposal site. Do not discharge into drains, water courses or onto the ground. Dispose in accordance with all applicable regulations.
<b>Special precautions</b>	Dispose in accordance with all applicable regulations.

### SECTION 14: Transport information

<b>ADR</b>	Not regulated as dangerous goods.
<b>IATA</b>	Not regulated as dangerous goods.
<b>IMDG</b>	Not regulated as dangerous goods.
<b>14.7. Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code</b>	MARPOL Annex II applies to liquids used in a ship's operation that pose a threat to the marine environment. These materials may not be transported in bulk.

### SECTION 15: Regulatory information

#### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

##### EU regulations

- Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex I**  
Not listed.
- Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex II**  
Not listed.
- Regulation (EC) No. 850/2004 On persistent organic pollutants, Annex I as amended**  
Not listed.
- Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 1 as amended**  
Not listed.
- Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 2 as amended**  
Not listed.
- Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 3 as amended**  
Not listed.
- Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex V as amended**  
Not listed.
- Regulation (EC) No. 166/2006 Annex II Pollutant Release and Transfer Registry**  
Not listed.
- Regulation (EC) No. 1907/2006, REACH Article 59(10) Candidate List as currently published by ECHA**  
Not listed.

## Authorisations

Regulation (EC) No. 1907/2006, REACH Annex XIV Substances subject to authorization, as amended

Not listed.

## Restrictions on use

Regulation (EC) No. 1907/2006, REACH Annex XVII Substances subject to restriction on marketing and use as amended

Not listed.

Directive 2004/37/EC: on the protection of workers from the risks related to exposure to carcinogens and mutagens at work

Not listed.

Directive 92/85/EEC: on the safety and health of pregnant workers and workers who have recently given birth or are breastfeeding

Not listed.

## Other EU regulations

Directive 96/82/EC (Seveso II) on the control of major-accident hazards involving dangerous substances

Not listed.

Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Not listed.

Directive 94/33/EC on the protection of young people at work

Not listed.

## Other regulations

The product is classified and labelled in accordance with EC directives or respective national laws. This Safety Data Sheet complies with the requirements of Regulation (EC) No 1907/2006. Pregnant women should not work with the product, if there is the least risk of exposure.

## National regulations

Young people under 18 years old are not allowed to work with this product according to the EU Directive 94/33/EC on the protection of young people at work. Follow national regulation for work with chemical agents.

## 15.2. Chemical safety assessment

No Chemical Safety Assessment has been carried out.

## SECTION 16: Other information

### List of abbreviations

Not available.

### References

GSK Hazard Determination

### Information on evaluation method leading to the classification of mixture

The classification for health and environmental hazards is derived by a combination of calculation methods and test data, if available.

### Full text of any statements or R-phrases and H-statements under Sections 2 to 15

R25 Toxic if swallowed.  
R28 Very toxic if swallowed.  
R36/37/38 Irritating to eyes, respiratory system and skin.  
R45 May cause cancer.  
R46 May cause heritable genetic damage.  
R48/20/22 Harmful: danger of serious damage to health by prolonged exposure through inhalation and if swallowed.  
R60 May impair fertility.  
R61 May cause harm to the unborn child.  
H300 Fatal if swallowed.  
H315 Causes skin irritation.  
H319 Causes serious eye irritation.  
H335 May cause respiratory irritation.  
H340 May cause genetic defects.  
H350 May cause cancer.  
H360FD May damage fertility. May damage the unborn child.  
H373 May cause damage to organs through prolonged or repeated exposure.

### Revision information

Product and Company Identification: Product and Company Identification  
Composition / Information on Ingredients: Undisclosed Ingredient Statement  
Physical & Chemical Properties:  
Toxicological Information:  
Ecological Information: Ecotoxicity  
Transport Information: Agency Name and Packaging Type/Transport Mode Selection  
Regulatory Information: Risk Phrases - Class.  
GHS: Classification

### Training information

Follow training instructions when handling this material.

**Disclaimer**

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.